Written by Jane Aubrey
In a monumental milestone for pediatric hematology, the U.S. Food and Drug Administration (FDA) has expanded the approval of Casgevy, the world’s first CRISPR-based gene therapy, to treat children as young as two years old suffering from severe sickle cell disease (SCD).
The FDA’s announcement, officially recorded in late July and heavily discussed in clinical circles throughout early August 2026, significantly broadens the patient population eligible for this potentially curative treatment. Previously, Casgevy, developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, was only approved for patients aged 12 and older who experienced recurrent vaso-occlusive crises.
Sickle cell disease is a devastating, inherited blood disorder characterized by the production of abnormal, sickle-shaped red blood cells. These rigid cells frequently clump together, blocking blood flow and causing excruciating pain crises, severe organ damage, and a drastically shortened life expectancy. For decades, treatment options were largely palliative, focused on pain management and blood transfusions.
Casgevy represents a paradigm shift. It is a one-time, ex vivo gene-editing therapy. The process involves extracting a patient’s own hematopoietic stem cells and using CRISPR/Cas9 technology to edit the BCL11A gene. This precise edit reactivates the production of fetal hemoglobin (HbF), a type of hemoglobin naturally produced during fetal development that does not sickle. The edited cells are then infused back into the patient following a rigorous conditioning regimen. The newly produced fetal hemoglobin effectively dilutes the defective adult hemoglobin, preventing the red blood cells from sickling and eliminating the debilitating pain crises.
The expansion of this approval to toddlers is critical because the cumulative organ damage caused by SCD begins in early childhood. By intervening at age two, clinicians can theoretically halt the progression of the disease before irreversible damage to the brain, kidneys, and spleen occurs.
However, the pediatric rollout of Casgevy is not without profound challenges. The therapy requires a brutal myeloablative conditioning regimen—essentially high-dose chemotherapy—to clear the bone marrow and make room for the edited stem cells. This process carries severe risks, including prolonged immunosuppression, severe infections, and potential long-term impacts on fertility. For a two-year-old, navigating this conditioning phase requires highly specialized, intensive pediatric critical care.
Furthermore, the logistical and financial hurdles remain immense. Casgevy carries a list price of $2.2 million. While Vertex has been working to establish value-based agreements with commercial payers and Medicaid programs, ensuring equitable access for the pediatric population—which is disproportionately comprised of Black and Hispanic children—will require sustained policy efforts. The treatment also requires extended hospital stays at specialized authorized treatment centers, placing a massive burden on families.
Despite these hurdles, the pediatric approval of Casgevy is a watershed moment. It moves the goalposts of SCD treatment from lifelong disease management to the very real possibility of a functional cure, offering thousands of young children the chance at a life free from the shadow of sickle cell crises.
